Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C48395
http://purl.obolibrary.org/obo/NCIT_C48395
|
|---|---|
| Preferred Name | Recombinant Human Papillomavirus Bivalent Vaccine |
| Definitions |
A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant, bivalent, human papillomavirus (HPV) vaccine, containing virus-like particles for HPV types 16 and 18 linked to the adjuvant ASO4, with potential immunoprotective and antineoplastic properties. Upon administration, HPV 16/18 L1 virus-like particle/ASO4 vaccine may generate humoral and cellular immunity against HPV types-16 and -18 antigens, thereby preventing cervical infection upon exposure to HPV types 16 and 18. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection. |
|---|---|
| prefLabel | Recombinant Human Papillomavirus Bivalent Vaccine
|
| label | Recombinant Human Papillomavirus Bivalent Vaccine
|
| PDQ_Closed_Trial_Search_ID | 442270
|
| code | C48395
|
| prefixIRI | NCIT:C48395
|
| in_subset |
See more
See less
|
| Display_Name | Recombinant Human Papillomavirus Bivalent Vaccine
|
| Preferred_Name | Recombinant Human Papillomavirus Bivalent Vaccine
|
| Contributing_Source | CTRP
|
| Maps_To | Recombinant Human Papillomavirus Bivalent Vaccine
|
| NCI_Drug_Dictionary_ID | 442270
|
| Legacy Concept Name | Human_Papillomavirus_16_18_L1_Virus-Like_Particle_AS04_Vaccine
|
| type | |
| ALT_DEFINITION | A vaccine used to prevent cervical cancer caused by human papillomaviruses (HPV) types 16 and 18. It is also used to prevent lesions that are caused by these viruses and that can lead to cervical, vulvar, or vaginal cancer. Cervarix is used in females aged 10-25 years. It is also being studied in the treatment of other medical conditions. It is a type of bivalent vaccine.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 442270
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C1721789
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |